comparemela.com

Latest Breaking News On - Enrollment practices - Page 5 : comparemela.com

Time to pull the plug on auto-renewed third party electric contracts!

Time to pull the plug on auto-renewed third party electric contracts! AARP Connecticut has worked for over a 17 years to address and rectify the fraud, misleading advertising and unscrupulous practices that have plagued and undermined Connecticut’s deregulated third-party electric market place. This has frequently resembled a game of whack-a-mole with a new scheme or trick popping up every time AARP and other consumer advocates knock down a deceptive supplier tactic through legislation or a Public Utilities Regulatory Authority ruling. John Erlingheuser Ratepayers in Connecticut pay the highest rates in the continental United States. Those entering third party electric supplier contracts to save money frequently find that what seems like a good deal initially turns into a costly mistake in the end. This is due to an anti-consumer provision of these supplier contracts that allows them to be auto-renewed at their conclusion.

Improving Diversity In Clinical Trials

Improving Diversity In Clinical Trials Source: Life Science Leader The lack of diversity in clinical trials isn’t a new problem, but in 2020 this issue rose to the forefront of the industry as a spotlight was cast on drug development as a whole due to the COVID pandemic. In fact, a key milestone related to this topic came in November 2020 when the FDA issued its final guidance, Enhancing the Diversity of Clinical Trial Populations Eligibility Criteria, Enrollment Practices, and Trial Designs. The experts in this ebook come from varying backgrounds, and as such, offer a myriad of recommendations relating to improving clinical trial enrollment of racial and ethnic minority groups

COVID proves clinical trials must proactively recruit people of color

COVID proves clinical trials must proactively recruit people of color Jo Wiederhorn, opinion contributor © Getty Images COVID proves clinical trials must proactively recruit people of color In the year since the start of the COVID-19 pandemic and the subsequent death of more than 500,000 Americans, researchers around the world have raced to develop vaccines at an unprecedented pace. But the quest to stop the pandemic in its tracks has collided with a long-standing problem: the lack of diversity in clinical trials. This issue must be addressed and the new federal administration can help. The Centers for Disease Control and Prevention report that Black Americans are 1.1 times as likely as white Americans to contract COVID-19, 2.9 times as likely to end up in the hospital and nearly twice as likely to die from it. Yet the communities hardest hit by illnesses like COVID-19 are also those grossly underrepresented in clinical trials for cures and therapeutics.

Turning Point In US History Our Chance To Do Better With Clinical Trials

Turning Point In U.S. History: Our Chance To Do Better With Clinical Trials By Charlotte Jones-Burton, MD, VP of Clinical Development-Nephrology, Otsuka Over a decade ago, I made the decision to transition from being a full-time physician to designing and executing clinical trials to help develop the innovative therapies that will transform and shape the future of medicine. As I transitioned to this new role, I could not help but notice there were not many people who looked like me a black woman. The more I became acclimated within the industry, the more heightened my awareness of the fractured healthcare system became.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.